FGFR inhibitor (Black Diamond Therapeutics)

N/A

Report date: 2025/03/20 16:05:49
NME

Base Information

Drug NameFGFR inhibitor (Black Diamond Therapeutics)
Drug Alias NameFGFR2/3 inhibitor (Black Diamond Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 2 antagonistsFibroblast growth factor receptor 3 antagonists
TargetsFibroblast growth factor receptor 2Fibroblast growth factor receptor 3
Therapy Area/IndicationsSolid tumoursAchondroplasiaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBlack Diamond Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBlack Diamond Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursAchondroplasia
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A